LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Inicio・Lista de Acciones・Ardelyx Inc

Ardelyx Inc

Cerrado

SectorSanidad

5.4

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

5.38

Máximo

5.54

Métricas clave
By Trading Economics
Ingresos	-37M -38M
Ventas	-31M 94M
BPA	-0.15
Margen de beneficios	-39.805
Empleados	489
EBITDA	-42M -32M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+204.43% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-54M 1.4B
Apertura anterior	5.4
Cierre anterior	5.4

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

59 / 344 Clasificación en Healthcare

Ardelyx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 jun 2026, 21:51 UTC

Principales Movimientos del Mercado

Merlin Shares Rally After Defense Department's Design Review Wraps

4 jun 2026, 23:46 UTC

Charlas de Mercado

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 jun 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 jun 2026, 23:42 UTC

Adquisiciones, fusiones, absorciones

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 jun 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

Energy Resources of Australia to Enter Trading Halt

4 jun 2026, 23:34 UTC

Charlas de Mercado

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 jun 2026, 23:08 UTC

Charlas de Mercado

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 jun 2026, 22:41 UTC

Charlas de Mercado

Australia Shares Set to Rise at the Open -- Market Talk

4 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 jun 2026, 20:44 UTC

Adquisiciones, fusiones, absorciones

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 jun 2026, 20:16 UTC

Charlas de Mercado

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 jun 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 jun 2026, 19:46 UTC

Charlas de Mercado

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 jun 2026, 19:38 UTC

Charlas de Mercado

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 jun 2026, 19:30 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 jun 2026, 18:47 UTC

Adquisiciones, fusiones, absorciones

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 jun 2026, 18:38 UTC

Ganancias

Money Quote: Tech Weakness in Context -- WSJ

4 jun 2026, 18:24 UTC

Ganancias

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 17:09 UTC

Charlas de Mercado

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 jun 2026, 16:58 UTC

Ganancias

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 16:46 UTC

Charlas de Mercado

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 jun 2026, 16:38 UTC

Ganancias

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 jun 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

4 jun 2026, 16:13 UTC

Charlas de Mercado

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 jun 2026, 16:11 UTC

Charlas de Mercado

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 jun 2026, 15:56 UTC

Charlas de Mercado

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparación entre iguales

Cambio de precio

Ardelyx Inc previsión

Precio Objetivo

By TipRanks

204.43% repunte

Estimación a 12 Meses

Media 16.5 USD 204.43%

Máximo 19 USD

Mínimo 13 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ardelyx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Ardelyx Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

59 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.